JBC Origene Your Gene Company

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M600480200 on May 17, 2006

J. Biol. Chem., Vol. 281, Issue 32, 23167-23179, August 11, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
281/32/23167    most recent
M600480200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cheng, K.-Y.
Right arrow Articles by Johnson, L. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cheng, K.-Y.
Right arrow Articles by Johnson, L. N.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

The Role of the Phospho-CDK2/Cyclin A Recruitment Site in Substrate Recognition*

Kin-Yip Cheng{ddagger}, Martin E. M. Noble{ddagger}, Vicky Skamnaki{ddagger}, Nick R. Brown{ddagger}, Ed D. Lowe{ddagger}, Luke Kontogiannis{ddagger}, Kui Shen§, Philip A. Cole§, Giuliano Siligardi, and Louise N. Johnson{ddagger}1

From the {ddagger}Laboratory of Molecular Biophysics, Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, United Kingdom, the §Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, and the Diamond Light Source, Chilton, Oxon OX11 0QX, United Kingdom

Phospho-CDK2/cyclin A, a kinase that is active in cell cycle S phase, contains an RXL substrate recognition site that is over 40 Å from the catalytic site. The role of this recruitment site, which enhances substrate affinity and catalytic efficiency, has been investigated using peptides derived from the natural substrates, namely CDC6 and p107, and a bispeptide inhibitor in which the {gamma}-phosphate of ATP is covalently attached by a linker to the CDC6 substrate peptide. X-ray studies with a 30-residue CDC6 peptide in complex with pCDK2/cyclin A showed binding of a dodecamer peptide at the recruitment site and a heptapeptide at the catalytic site, but no density for the linking 11 residues. Kinetic studies established that the CDC6 peptide had an 18-fold lower Km compared with heptapeptide substrate and that this effect required the recruitment peptide to be covalently linked to the substrate peptide. X-ray studies with the CDC6 bispeptide showed binding of the dodecamer at the recruitment site and the modified ATP in two alternative conformations at the catalytic site. The CDC6 bispeptide was a potent inhibitor competitive with both ATP and peptide substrate of pCDK2/cyclin A activity against a heptapeptide substrate (Ki = 0.83 nM) but less effective against RXL-containing substrates. We discuss how localization at the recruitment site (KD 0.4 µM) leads to increased catalytic efficiency and the design of a potent inhibitor. The notion of a flexible linker between the sites, which must have more than a minimal number of residues, provides an explanation for recognition and discrimination against different substrates.


Received for publication, January 17, 2006 , and in revised form, March 13, 2006.

The atomic coordinates and structure factors (code 2CCI (CDC6 peptide complex) and 2CCH (CDC6 bispeptide complex)) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

* This work was supported by the Medical Research Council, the European Community's Human Potential Programme under Contract HPRN-CT-2002-00252 (CAMKIN), the Wellcome Trust, and the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom correspondence should be addressed: Laboratory of Molecular Biophysics, Dept. of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK. Tel.: 44-1865-275365; Fax: 44-1865-285353; E-mail: louise.johnson{at}biop.ox.ac.uk.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
S. A. Dames, A. Schonichen, A. Schulte, M. Barboric, B. M. Peterlin, S. Grzesiek, and M. Geyer
Structure of the Cyclin T binding domain of Hexim1 and molecular basis for its recognition of P-TEFb
PNAS, September 4, 2007; 104(36): 14312 - 14317.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Koga, N. Yamaguchi, T. Abe, M. Minegishi, S. Tsuchiya, M. Yamamoto, and N. Minegishi
Cell-cycle-dependent oscillation of GATA2 expression in hematopoietic cells
Blood, May 15, 2007; 109(10): 4200 - 4208.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.